Estimates of Drug Development Costs (various)
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAG
1
YearShort CitePeriodTransparency of dataConstant dollar yearOut-of- Pocket Pre-ClinicalOut-of- Pocket Trial outlaysLoA, when human tests beginRisk adjusted: PreclinicalRisk adjusted: TrialsReal CoCRisk and CoC adjusted PreclinicalRisk and CoC adjusted TrialsRisk adjusted, total (k+l)Risk and CoC adjusted, Total (o+p)Clinical share (p/s)CoC share, (s-r)/sAdjustment to 2017 dllarsRisk adjusted, total in 2017 dollarsRisk and CoC adjusted, Total in 2017 dollarsNotes
2
1972Schnee (1972)1950-1967, market introductionscurrent0.534
3
1979Hansen (1979)NCE's entering human testing 1963 to 1975, US firms1967$78%$18$12$3039%.1744$169
4
1979Hansen (1979)NCE's entering human testing 1963 to 1975, US firms19764.197.1250$128%$33$21$5439%.2917$185
5
1991DiMasi et al. (1991). Select originated NCE, first tested in humans 1970 to 1982Proprietary sample, CSDD database1987$11.2300$66$48$156$75$114$23133%51%.5280$215$437
6
1993OTA (1993)DiMasi 1991 reestimated with higher discount rate for preclinical periodProprietary sample, CSDD database1990$359.5888$610
7
2001
TB Alliance (2001), established economies
2000$11$27.2300$46$49$95$24060%.7220$132$332
8
2003DiMasi et al. (2003). NCE, first in humans, 1983-19942000$125.2150$121$282$335$467$403$80258%50%.7220$558$1,111
9
2006Adams & Brantner (2006).First-in-humans, 1989–2002
Proprietary Pharmaprojects database
2000$868.7220$1,202
10
2007DiMasi and Grabowski (2007a)First-in-humans, 1990–2003 (large molecule)2005$60$166.3020$198$36111.5%$615$626$559$1,24150%55%.8582$651$1,446
11
2010Adams & Brantner (2010). Company R&D expenditures, 1985–20012000$1,200.7220$1,662
12
2010Paul (2010)$18.50$205.1170$281$54811%$824$906$873$1,77851%51%0.8924$978$1,992
13
2012OHE (2012)New drug
Unpublished data from various CMRI surveys
2011$235.0700$86$92511%$207$1,299$1,011$1,50686%33%.9109$1,109$1,653
14
2016DiMasi et al. (2016). NME, Initial human testing anywhere in the world for these compounds occurred during the period 1995–2007. Development costs were obtained through 2013.Confidential sample from CSDD database2013$339.1183$430$96510.5%$1,098$1,460$1,395$2,55857%45%.9426$1,480$2,714
15
2017Love (2017b)Orphan Indications approved 2010 to 2016
US treasury reports of Credit outlays
current$94
16
2017Vinay, Malilankody (2017)NME, 9 of 10 were orphan approvalsCompany SEC filings2017.23257%$648$75714%1.0000$648$757
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Loading...
 
 
 
Costs of New Drug
Citations, with URLs
Trial costs
Trial costs, per approval
Trials costs, per patient
Preclinical outlays per NME
CoC
GDPDEF
 
 
Main menu